|
Advances in the Stem Cell Industry: The future impact of innovation, and an evaluation of the commercial landscape
|
Caracteristicas de este estudio de mercado: | 162 Pages | |||||||||
| Sobre este articulo de mercado: |
An important milestone in the development of stem cell technology occurred in 2007, when researchers induced human cells into a stem cell state using defined genetic factors. These cells are now known.....
An important milestone in the development of stem cell technology occurred in 2007, when researchers induced human cells into a stem cell state using defined genetic factors. These cells are now known as induced pluripotent stem (IPS) cells; they offer an alternative to using embryonic stem cells. This report takes the implications of IPS cells and other developments into account. Some essential technologies are already in place and stem-cell based therapies have already begun to appear in the marketplace. This has enabled the author to build market estimates based on emerging commercial realities. The stem cell market is already divided into three segments—cell-based treatments, umbilical cord blood banking, and the use of stem cells to evaluate the efficacy and safety of new drugs developed by other methods. Global sales reached $410 million in 2008, and will grow to $2.68 billion by 2012. This growth will reach a projected $5.1 billion in 2014, providing a realistic, and even cautious forecast of the commercial potential these segments. The report also describes the potential for stem cell science as applied to drug discovery and toxicity testing To give a full industry perspective, the report offers profiles of a large number (approximately 50) of companies operating in this field, including all sizes and types of organisation from small start-ups based on a single technology to large concerns with established product portfolios. This report also describes the background of stem cell science and the current status of knowledge in this sphere. The approach does not shirk essential technical detail but it is written in an easily readable style and the depth of information provided is carefully assessed. Key features of this report Provides current status of the stem cell market, essential in a fast-moving field where up-to-date knowledge is paramount. Another key quality for a report such as this is that it should be realistic. Whether one describes the glass as half-full or half-empty matters less than describing it as a half glassful. Market forecasts are refined to indicate the potential offered by this exciting new area of technology without ignoring the practical difficulties. The scope for medical applications of stem cell science is broad and the report attempts to give as full a picture as possible, including applications that are as yet in development as well as those which are more advanced. The report also describes the potential for stem cell science as applied to drug discovery and toxicity testing To give a full industry perspective, the report offers profiles of a large number (approximately 50) of companies operating in this field, including all sizes and types of organisation from small start-ups based on a single technology to large concerns with established product portfolios. The report describes the background of stem cell science and the current status of knowledge in this sphere. The approach does not shirk essential technical detail but it is written in an easily readable style and the depth of information provided is carefully assessed. Key findings from this report The main focus of applied stem cell research has been to explore the possibilities of using SCs in regenerative medicine, to replace normal cells and tissues destroyed by disease or trauma. Primary therapeutic targets are nervous system disorders such as Parkinson’s disease and amyotrophic lateral sclerosis; cardiovascular disease including heart failure, myocardial infarction and severe peripheral arterial disease.. Stem cell science also offers the prospect of contributing to new drug discovery, for example by providing in vitro targets that can identify promising new candidates before any in vivo work has been undertaken. Cell-based therapies may be divided into those using autologous cells and those using allogeneic cells. Each market has its own characteristics. The world market for cell-based therapies is now estimated at $600 million, but there is great growth potential, given the high prevalence of eligible patients, once appropriate products reach the marketplace. The US accounts for about 90% of the world market but other national markets will make inroads over the coming years, and grow faster than the US market. Attrition among companies and products in the regenerative medicine market indicate that this is a demanding market environment requiring care in the choice of appropriate marketing model. Key questions answered by this report What are the main hitherto untreatable conditions for which stem cell therapy may provide new hope of cure? Are embryo or adult stem cells the best prospect for future commercialization? What is the present size of the global stem cell market, and how is it expected to grow? Which are the leading national markets for stem cell products? What is the nature of the ethical objection to stem cell manipulation? What important factors need to be taken into account when formulating a business plan for stem cell commercialization. Names the leading companies with stem cell products in advanced development. Apart from the treatment of disease, what other roles are envisaged for stem cell products? What are induced pluripotent stem cells, and why are they important? Companies mentioned in the report Brainstorm Genzyme International Stem Cell Corporation MedCell MediStem NuVasive Opexa Osiris Plureon Report Highlights [Cerrar las informaciones del articulo de mercado] |
|||||||||||
|
Table of Contents Advances in the Stem Cell Industry Executive summary 10 Background 10 Stem cell research and development: scope and status 10 Commercial landscape 11 Industry landscape 12 Chapter 1 Background 16 Summary 16 Introduction 17 The building blocks of life 17 About stem cells 18 Potency 20 Stem cell division 21 Stem cell research 21 Human ESCs 23 Current status of knowledge 24 Embryonic stem cells 24 Growth and identification of ESCs 25 Stimulating ESCs to differentiate 26 Adult stem cells 26 Cord blood stem cells 29 Induced pluripotent stem cells 30 Nuclear reprogramming 31 Ethical and regulatory issues 33 Situation in the US 33 European regulations 34 Chapter 2 Stem cell research and development: scope and status 38 Summary 38 Introduction 39 Practical applications of stem cells 39 Disease treatment 40 Amyotrophic lateral sclerosis 40 Parkinson's disease 43 Spinal cord injury 44 Alzheimer’s disease 46 Cancer 48 Heart disease 49 Peripheral arterial disease 52 Type 1 diabetes 55 Liver failure 59 Graft-versus-host disease 60 Stem cell models: applications in drug discovery 61 Screening studies 61 Toxicity studies 63 Practical benefits 64 Some skepticism remains 65 Chapter 3 Commercial landscape 68 Summary 68 Resisting the hyperbole 69 Market realities 70 Cell-based therapy market 70 Autologous SC therapy 71 Allogeneic SC therapy 71 Cord blood banks 71 Market drivers 72 Market 73 Global market estimates and forecasts 74 Global market by use 75 Global market by country share 76 Embryo vs. adult stem cells 77 Investment opportunities 78 Choosing a viable business model 79 Matching the model to the circumstance 80 Autologous therapy models 80 Allogeneic therapy models 83 Chapter 4 Industry landscape 86 Summary 86 Introduction 87 Company profiles 89 Aastrom Biosciences, Inc. 89 Overview 89 Pipeline 90 Advanced Cell Technology, Inc. 90 Overview 91 Pipeline 91 Collaboration 92 Aldagen 92 Overview 92 Pipeline 92 Collaboration 93 Angioblast Systems, Inc. 93 Overview 93 Pipeline 94 Athersys, Inc. 95 Overview 95 Pipeline 95 Collaboration 96 Financials 96 Bioheart, Inc. 97 Overview 97 Pipeline 97 Bionet 98 Overview 99 Collaboration 99 Brainstorm Cell Therapeutics 99 Overview 100 Capricor, Inc. 101 Overview 101 Pipeline 101 Collaboration 102 Cardio3 BioSciences SA 102 Overview 102 Cellcyte Genetics 103 Overview 103 Pipeline 103 Collaboration 104 Cellerix SA 104 Overview 104 Pipeline 105 CellGenix Technologie Transfer 105 Overview 106 Cytori Therapeutics, Inc. 107 Overview 107 Entest BioMedical, Inc. 107 Overview 108 ES Cell International 108 Overview 109 EvoStem Finland Oy 109 Overview 110 Fate Therapeutics, Inc. 110 Overview 110 Genzyme 112 Collaboration 113 Financials 113 Geron 113 Overview 113 Pipeline 114 Healtheuniverse, Inc. 114 Overview 115 Innovacell Biotechnologie AG 115 Overview 116 International Stem Cell Corporation (ISCO) 116 Overview 116 Financing 118 iPierian, Inc. 118 Overview 118 Ixion Biotechnology, Inc. 119 Overview 119 Karocell Tissue Engineering AB 120 Overview 120 MedCell Bioscience Ltd 121 Overview 121 MediStem, Inc. 122 Overview 122 Pipeline 123 Mesoblast Limited 124 Overview 125 Nephrogenix 126 Overview 126 Neuralstem, Inc. 127 Overview 127 Pipeline 128 Collaboration 128 OncoStem Pharma 128 Overview 128 Novocell, Inc. 129 Overview 129 NuVasive, Inc. 130 Overview 130 Osiris Therapeutics, Inc. 131 Overview 131 Pipeline 131 Collaboration 132 Financials 133 Pharmicell Europe GmbH 133 Overview 133 PrimeGen Biotech 134 Overview 135 Opexa Therapeutics 136 Overview 136 Financing 136 Financials 137 Plureon 137 Overview 137 Pipeline 138 Collaboration 138 Proteonomix, Inc. 139 Overview 139 Regenerative Sciences, Inc. 140 Overview 140 ReNeuron 140 Overview 141 Pipeline 141 Shenzhen Beike 143 Overview 143 Stematix, Inc. 143 Overview 144 StemCells, Inc. 145 Overview 145 Stem Cell Therapeutics 146 Overview 147 Stem Cell Therapy International 147 Overview 147 Stemedica Cell Technologies, Inc. 148 Overview 148 Stempeutics Research Pvt. Ltd. 149 Overview 150 t2cure GmbH 150 Overview 151 TICEBA GmbH 152 Overview 152 Tristem 153 Overview 153 Chapter 5 Appendix 154 Methodology 154 Glossary 155 Index 162 [Cerrar la tabla de contenidos] |
||||||||||||
|
Table 3.1: Global stem cell market ($m), 2008-14 74 Table 3.2: Potential US patient populations for cell-based therapies 75 Table 3.3: Stem cell market by main uses ($m), 2008-14 76 Table 3.4: Country breakdown of stem cell market ($m), 2008-14 77 Table 3.5: Leading cell-based regenerative medicine products 79 Figure 1.1: Early embryonic development and later differentiation 19 Figure 1.2: Stem cell division 21 Figure 1.3: Induced pluripotent stem cells 31 Figure 2.4: Stem cell opportunities in disease treatment and R&D 40 Figure 3.5: Forces affecting the stem cell market 73 Figure 3.6: Key challenges faced when developing autologous therapy 83 Figure 4.7: Type and number of regenerative medicine organizations 87 [Ocultar lista de tablas / figuras] |
||||||||||||
| Precio ** (Formato del reporte): |
libre de costos de envio **Importante: Todos los precios son netos sin impuestos. Depende del país y de su tipo de empresa para pagar los impuestos. Si usted nos da su dirección de facturación, el monto total correcto será indicado en la siguiente orden de proceso. Para más información de impuestos y precios usted nos encuentra en nuestros FAQs |
|||||||||||
